体重下降对2型糖尿病缓解的影响:随机对照试验的系统综述与元回归分析
该系统综述与元回归分析纳入22篇随机对照试验报告,分析体重下降程度与2型糖尿病缓解率的关系。结果显示每减轻1个百分点体重,完全缓解概率增加2.17个百分点,部分缓解概率增加2.74个百分点;年龄、性别、种族、糖尿病病程、基线BMI、HbA1c、胰岛素使用及减重干预类型与缓解无显著关联。
要点
- 体重下降<10%时完全缓解合并比例为0.7%,20-29%时为49.6%,≥30%时为79.1%。
- 每减轻1个百分点体重,完全缓解概率增加2.17个百分点(95%CI 1.94-2.40)。
- 年龄、性别、种族、糖尿病病程、基线BMI、HbA1c、胰岛素使用及干预类型与缓解无显著关联。
核心结论
- 观察到体重下降与糖尿病缓解之间存在稳健的剂量反应关系,且独立于年龄、糖尿病病程、HbA1c、BMI和干预类型。
- 这些发现凸显了体重下降在管理2型糖尿病和降低糖尿病相关并发症风险中的关键作用。
研究设计与样本
- 系统综述与元回归分析,遵循Cochrane和PRISMA指南,系统检索PubMed、Embase和试验注册库自建库至2024年7月30日的随机对照试验。
- 纳入在超重或肥胖的2型糖尿病患者中开展的随机对照试验,共识别22篇相关文献,涵盖29项完全糖尿病缓解结局指标和33项部分缓解结局指标。
- 完全缓解定义为HbA1c<6.0%(42 mmol/mol)或空腹血糖<100 mg/dL(5.6 mmol/L)或两者兼有,且未使用降糖药物;部分缓解定义为HbA1c<6.5%(48 mmol/mol)或空腹血糖<126 mg/dL(7.0 mmol/L)或两者兼有,且未使用降糖药物,评估时间点为体重下降干预后至少1年。
- 研究方案已在PROSPERO注册(CRD42024497878)。
主要发现
- 干预后1年完全缓解的合并平均比例:体重下降<10%者为0.7%(95%CI 0.1-4.6),体重下降20-29%者为49.6%(95%CI 40.4-58.9),体重下降≥30%者为79.1%(95%CI 68.6-88.1);无研究报告体重下降10-19%者的完全缓解数据。
- 干预后1年部分缓解的合并平均比例:体重下降<10%者为5.4%(95%CI 2.9-8.4),体重下降10-19%者为48.4%(95%CI 36.1-60.8),体重下降20-29%者为69.3%(95%CI 55.8-81.3),体重下降≥30%者为89.5%(95%CI 80.0-96.6)。
- 体重每下降1个百分点,达到完全缓解的概率增加2.17个百分点(95%CI 1.94-2.40),达到部分缓解的概率增加2.74个百分点(95%CI 2.48-3.00)。
- 年龄、性别、种族、糖尿病病程、基线BMI、HbA1c、胰岛素使用或体重下降干预类型与缓解之间未观察到显著或可觉察的关联。
- 总体数据来源于在所有质量领域均低偏倚风险的随机对照试验。
局限性
- 无研究报告体重下降10-19%者的完全缓解数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bodyweight loss is associated with type 2 diabetes remission; however, the quantitative relationship between the degree of bodyweight loss and the likelihood of remission, after controlling for confounding factors, remains unknown. We aimed to analyse the relationship between the degree of bodyweight loss and diabetes remission after controlling for various confounding factors, and to provide estimates for the effect sizes of these factors on diabetes remission. METHODS: This systematic review and meta-regression analysis followed Cochrane and PRISMA guidelines to systematically review, synthesise, and report global evidence from randomised controlled trials done in individuals with type 2 diabetes and overweight or obesity. The outcome was the proportion of participants with complete diabetes remission (HbA1c <6·0% [42 mmol/mol] or fasting plasma glucose [FPG] <100 mg/dL [5·6 mmol/L], or both, with no use of glucose-lowering drugs) or partial diabetes remission (HbA1c <6·5% [48 mmol/mol] or FPG <126 mg/dL [7·0 mmol/L], or both, with no use of glucose-lowering drugs) at least 1 year after a bodyweight loss intervention. We searched PubMed, Embase, and trial registries from database inception up to July 30, 2024. Data were extracted from published reports. Meta-analyses and meta-regressions were performed to analyse the data. The study protocol is registered with PROSPERO (CRD42024497878). FINDINGS: We identified 22 relevant publications, encompassing 29 outcome measures of complete diabetes remission and 33 outcome measures of partial remission. The pooled mean proportion of participants with complete remission 1 year after the intervention was 0·7% (95% CI 0·1-4·6) in those with bodyweight loss less than 10%, 49·6% (40·4-58·9) in those with bodyweight loss of 20-29%, and 79·1% (68·6-88·1) in those with bodyweight loss of 30% or greater; no studies reported on complete remission with 10-19% bodyweight loss. The pooled mean proportion of participants with partial remission 1 year after the intervention was 5·4% (95% CI 2·9-8·4) in those with bodyweight loss less than 10%, 48·4% (36·1-60·8) in those with 10-19% bodyweight loss, 69·3% (55·8-81·3) in those with bodyweight loss of 20-29%, and 89·5% (80·0-96·6) in those with bodyweight loss of 30% or greater. There was a strong positive association between bodyweight loss and remission. For every 1 percentage point decrease in bodyweight, the probability of reaching complete remission increased by 2·17 percentage points (95% CI 1·94-2·40) and the probability of reaching partial remission increased by 2·74 percentage points (2·48-3·00). No significant or appreciable associations were observed between age, sex, race, diabetes duration, baseline BMI, HbA1c, insulin use, or type of bodyweight loss intervention and remission. Overall, data were derived from randomised controlled trials with a low risk of bias in all quality domains. INTERPRETATION: A robust dose-response relationship between bodyweight loss and diabetes remission was observed, independent of age, diabetes duration, HbA1c, BMI, and type of intervention. These findings highlight the crucial role of bodyweight loss in managing type 2 diabetes and reducing the risk of diabetes-related complications. FUNDING: Biomedical Research Program at Weill Cornell Medicine-Qatar and the Qatar National Research Fund (a member of Qatar Foundation).
引用
- Kanbour S, Ageeb RA, Malik RA, et al. Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025. PMID: 40023186. doi:10.1016/S2213-8587(24)00346-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。